A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) (NCT06818643)
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
Who can join: Review the eligibility criteria below.
Location: The University of Alabama at Birmingham ( Site 1005) — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (49 Sites)
Showing the first 25 of 49 sites.
- The University of Alabama at Birmingham ( Site 1005) — Birmingham, Alabama
- University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1003) — Miami, Florida
- John Theurer Cancer Center at Hackensack University Medical Center ( Site 1009) — Hackensack, New Jersey
- NEXT Oncology ( Site 1010) — Austin, Texas
- NEXT Oncology ( Site 1011) — Houston, Texas
- NEXT Oncology ( Site 1012) — Irving, Texas
- Virginia Commonwealth University ( Site 1008) — Richmond, Virginia
- Centro de Estudios Clínicos SAGA ( Site 0033) — Santiago, Region M. de Santiago
- FALP ( Site 0031) — Santiago, Region M. de Santiago
- Pontificia Universidad Catolica de Chile ( Site 0032) — Santiago, Region M. de Santiago
- Bradford Hill Centro de Investigaciones Clinicas ( Site 0030) — Santiago, Region M. de Santiago
- Peking University First Hospital ( Site 0180) — Beijing, Beijing Municipality
- Chongqing Cancer Hospital ( Site 0186) — Chongqing, Chongqing Municipality
- Hunan Cancer Hospital ( Site 0181) — Changsha, Hunan
- The First Hospital of Jilin University ( Site 0185) — Changchun, Jilin
- West China Hospital Sichuan University ( Site 0187) — Chengdu, Sichuan
- Institut Paoli Calmettes ( Site 0053) — Marseille, Bouches-du-Rhone
- Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer-Medical Oncology ( Site 0054) — Rennes, Ille-et-Vilaine
- Centre Oscar Lambret ( Site 0051) — Lille, Nord
- Gustave Roussy ( Site 0050) — Villejuif, Val-de-Marne
- Rambam Health Care Campus ( Site 0082) — Haifa,
- Rabin Medical Center ( Site 0081) — Petah Tikva,
- Sheba Medical Center ( Site 0080) — Ramat Gan,
- National Cancer Center Hospital East ( Site 0190) — Kashiwa, Chiba
- Cancer Institute Hospital of JFCR ( Site 0192) — Koto, Tokyo
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumors
- A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma — Scottsdale, Arizona
- A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer — Orange, California
- QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations — Denver, Colorado
- A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors — Denver, Colorado
- A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer — Scottsdale, Arizona
- A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations — Los Angeles, California
Explore by condition: All Advanced Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.